Good morning :)
$
₹
T

Telix Pharmaceuticals Limited

TLX

NASDAQ
T

Telix Pharmaceuticals Limited

TLX

NASDAQ
$8.971.92% (-0.17)
$
₹
$8.971.92% (-0.17)
High
—
—
Low
—
—
Returns
—
—
Loading...
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max

Healthcare

Biotechnology

Mid Cap

With a market cap of $3.1B the stock is ranked 1757

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

91.5
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

8.24
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$0.1
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

—
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

3.76%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Analyst Ratings & Forecast

Analyst Ratings & Forecast

Detailed Forecast Detailed Forecast 

Based on 5 analysts reports

Buy
5 analysts
Hold
0 analyst
Sell
0 analyst

Price Upside

+124.24%

Earnings Growth

+210.94%

Rev. Growth

+15.51%

See Detailed Forecast

Company Profile

Company Profile

Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer. The company develops TLX250, an rADC for treating advanced metastatic kidney cancer; TLX101, a systemic therapy for the treatment of glioblastoma; TLX66, a product candidate for bone marrow conditioning for hematopoietic stem cell transplant conditioning; and Illuccix and Gozellix for the treatment of prostate cancer. The company is also developing TLX592, a prostate cancer therapy candidate for targeted alpha therapy based on its proprietary RADmAb-engineered antibody technology; TLX252 for the treatment of patients with advanced metastatic kidney cancer; TLX400, a bladder fibroblast activation protein for treating various tumors; TLX102, a large amino acid transporter-targeting small molecule-based alpha therapy candidate for the treatment of glioblastoma and multiple myeloma; TLX300 for treating soft tissue sarcoma; and TLX090, a bone-seeking agent for bone metastases and pain palliation. In addition, it is developing BiPASS, which is in Phase 3 clinical trial for prostate cancer diagnosis; AlFluor, a novel PET radiochemistry solution; TLX250-Px, a PET diagnostic imaging agent; and TLX101-Px, a radiolabeled amino acid PET agent. It operates in Australia, Belgium, Canada, the United Kingdom, the United States, and internationally. The company has strategic collaboration with University Hospital Essen. The company was founded in 2015 and is headquartered in North Melbourne, Australia.
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer. The company develops TLX250, an rADC for treating advanced metastatic kidney cancer; TLX101, a systemic therapy for the treatment of glioblastoma; TLX66, a product candidate for bone marrow conditioning for hematopoietic stem cell transplant conditioning; and Illuccix and Gozellix for the treatment of prostate cancer. The company is also developing TLX592, a prostate cancer therapy candidate for targeted alpha therapy based on its proprietary RADmAb-engineered antibody technology; TLX252 for the treatment of patients with advanced metastatic kidney cancer; TLX400, a bladder fibroblast activation protein for treating various tumors; TLX102, a large amino acid transporter-targeting small molecule-based alpha therapy candidate for the treatment of glioblastoma and multiple myeloma; TLX300 for treating soft tissue sarcoma; and TLX090, a bone-seeking agent for bone metastases and pain palliation. In addition, it is developing BiPASS, which is in Phase 3 clinical trial for prostate cancer diagnosis; AlFluor, a novel PET radiochemistry solution; TLX250-Px, a PET diagnostic imaging agent; and TLX101-Px, a radiolabeled amino acid PET agent. It operates in Australia, Belgium, Canada, the United Kingdom, the United States, and internationally. The company has strategic collaboration with University Hospital Essen. The company was founded in 2015 and is headquartered in North Melbourne, Australia.

Peers

Compare with peers Compare with peers 

Peers

Compare with peers Compare with peers 
Eli Lilly and Company
LLY
Eli Lilly and Company
P/E Ratio
42.74
42.74
1Y Return
55.33%
55.33%
Buy Reco %
83.87
83.87
Johnson & Johnson
JNJ
Johnson & Johnson
P/E Ratio
40.03
40.03
1Y Return
37.93%
37.93%
Buy Reco %
69.56
69.56
Merck & Company Inc
MRK
Merck & Company Inc
P/E Ratio
115.29
115.29
1Y Return
66.63%
66.63%
Buy Reco %
70.37
70.37
Novartis AG ADR
NVS
Novartis AG ADR
P/E Ratio
22.82
22.82
1Y Return
14.79%
14.79%
Buy Reco %
41.66
41.66
AstraZeneca PLC
AZN
AstraZeneca PLC
P/E Ratio
25.78
25.78
1Y Return
1.93%
1.93%
Buy Reco %
83.33
83.33
Compare with Peers

Forecast

Forecast

Price

Revenue

Earnings

Price Forecast

Price Forecast

2026
Current$9.15Baseline
Analyst Target - 1 year
Target$20.52+124.24%

All values in $

20232024202520262027$10.70$14.66$18.61Target+124.24%
2026
Current$9.15Baseline
Analyst Target - 1 year
Target$20.52+124.24%

All values in $

Revenue Forecast

Revenue Forecast

Lower revenue growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The next fiscal year's mean estimate implies 15.51% growth, versus a trailing 3-year CAGR of 96.00%.

2025
Current$1.20Baseline
Forecast for Dec 2026
High$1.43+19.2%
Average$1.39+15.51%
Low$1.37+14.18%

All values in $ Billion

2021202220232024202520260.000.160.500.781.20Low+14.18%Average+15.51%High+19.2%
2025
Current$1.20Baseline
Forecast for Dec 2026
High$1.43+19.2%
Average$1.39+15.51%
Low$1.37+14.18%

All values in $ Billion

Earnings Per Share Forecast

Earnings Per Share Forecast

2025
Current$0.05Baseline
Forecast for Dec 2026
High$0.43+723.42%
Average$0.16+210.94%
Low$0.03-44.34%

All values in $

20222023202420252026N/AN/A0.060.05Low-44.34%Average+210.94%High+723.42%
2025
Current$0.05Baseline
Forecast for Dec 2026
High$0.43+723.42%
Average$0.16+210.94%
Low$0.03-44.34%

All values in $

Financials

Financials

Income

Balance Sheet

Cash Flow

594.2
38.2
593.1
-3.4
620.4
-7.2
691.3
55.5
Q4 2024
Q2 2025
Q4 2025
Q2 2026
Revenue
Net Income
Financial YearQ4 2021Q2 2022Q4 2022Q2 2023Q4 2023Q2 2024Q4 2024Q2 2025Q4 2025Q2 2026
Total Revenue4.6824.04136.04220.83281.71188.96594.24593.11620.44691.36
Net Income-47.99-70.89-33.18-14.3219.5311.6838.23-3.48-7.2555.51
Net Profit Margin-1024.24%-294.80%-24.39%-6.48%6.93%6.18%6.43%-0.58%-1.16%8.02%
See CostsAll values in $ Million

Peers

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareBiotechnology

Valuation

Returns

Forecast

ScreenerCompare valuation on Screener
StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
Telix Pharmaceuticals Limited 91.58.24-
Eli Lilly and Company42.7430.781.15
Johnson & Johnson40.037.632.82
ScreenerCompare valuation on Screener

Price Comparison

Price Comparison

Compare TLX with any stock or ETF
Compare TLX with any stock or ETF
Comparing from
TLX
LLY
JNJ
Loading...

Frequently asked questions

  1. Telix Pharmaceuticals Limited (TLX) share price today is $8.97 as of October 27, 2026 at 1:21 AM IST. The stock touched a day high of $9.00 and a day low of $8.92.

  2. Telix Pharmaceuticals Limited stock trades on NASDAQ under the ticker symbol TLX.

  3. Telix Pharmaceuticals Limited's market capitalization is $3.1B as of October 27, 2026 at 1:21 AM IST.

  4. Telix Pharmaceuticals Limited's price-to-earnings (P/E) ratio is 91.5 as of October 26, 2026.

  5. Telix Pharmaceuticals Limited's price-to-book (P/B) ratio is 8.24 as of October 26, 2026.

  6. Yes, You can buy Telix Pharmaceuticals Limited shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy Telix Pharmaceuticals Limited shares in three steps: 1. Search Telix Pharmaceuticals Limited on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since Telix Pharmaceuticals Limited trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in Telix Pharmaceuticals Limited (TLX) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 1.1143 shares at the current price of $8.97.

Loading...